PCSK9 Inhibitors

systematic review meta-analysis network meta-analysis

Select cardiovascular prevention All type of patient       PCSK9 Inhibitor alirocumabbococizumabevolocumab      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	serious adverse events (15)death from all causes as adverse event (14)cardiovascular death as adverse event (8)cardiovascular events as adverse event (4)Neurocognitive disorder (4)myocardial infarction as adverse event (3)Muscle-related adverse events (3)cardiovascular events (2)Cardiovascular death (2)All cause death (2)neurological SAE (1)Allergic reactions (1)Coronary event (1)Coronary death (1)stroke (fatal and non fatal) (1)myocardial infarction (fatal and non fatal) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	serious adverse events	death from all causes as adverse event
cardiovascular prevention
alirocumab
ODYSSEY OPTIONS I	alirocumab	ezetimibe (on top statin)				negative
ODYSSEY OPTIONS II	alirocumab	ezetimibe (on top statin)				negative
ODYSSEY MONO      NCT	alirocumab	ezetimibe alone			Low risk of bias	negative
ODYSSEY Long-Term, 2015      NCT	alirocumab	placebo (on top statins)			Exploratory	suggesting
ODYSSEY Alternative      NCT	alirocumab	placebo (on top statins)			Low risk of bias	negative
ODYSSEY OUTCOMES, 2018      NCT	alirocumab	placebo (on top statins)			Low risk of bias	conclusive
ODYSSEY FH 1      NCT	alirocumab	placebo (on top statins)			Low risk of bias	-
ODYSSEY FH 2      NCT	alirocumab	placebo (on top statins)			Low risk of bias	-
ODYSSEY HIGH FH      NCT	alirocumab	placebo (on top statins)				negative
ODYSSEY COMBO        NCT	alirocumab	placebo (on top statins)			Low risk of bias	negative
ODYSSEY COMBO II        NCT	alirocumab	placebo (on top statins)			Low risk of bias	negative
evolocumab
MENDEl 2    NCT	evolocumab					-
Mendel 1, 2012      NCT	evolocumab					-
YUKAWA-1, 2014	evolocumab					-
GAUSS 2    NCT	evolocumab	ezetimibe alone				negative
GAUSS 1, 2012    NCT	evolocumab	placebo				negative
DESCARTES, 2014    NCT	evolocumab	placebo (on top statins)				negative
LAPLACE-TIMI 57    NCT	evolocumab	placebo (on top statins)				-
RUTHERFORD-1    NCT	evolocumab	placebo (on top statins)				negative
LAPLACE 2, 2014    NCT	evolocumab	placebo (on top statins)				negative
RUTHERFORD-2, 2015    NCT	evolocumab	placebo (on top statins)				negative
FOURIER, 2017      NCT	evolocumab	placebo (on top statins)			Low risk of bias	conclusive